Restructuring Costs to Address the End of COVID-19-Related Revenue

Pfizer (PFE) is expanding its cost-cutting target to $6.7 billion by 2029 to address declining COVID-19 revenue and patent expiration pressures. Comirnaty (tozinameran), co-developed with BioNTech (BNTX), is an approved and marketed mRNA vaccine targeting the SARS-CoV-2 spike protein, which received full FDA approval on August 23, 2021. However, revenue decreased from $37.8 billion in 2022 to $4.4 billion in 2025. In 2025, total COVID-19 product revenue, including Paxlovid (nirmatrelvir/ritonavir), was approximately $6.5 billion, with a projected $5 billion in 2026. This restructuring is more focused on redesigning fixed costs to align with reduced revenue rather than responding to temporary fluctuations in demand.

Clinical Failures and Market Withdrawals Increase Capital Allocation Burden

Sigvotatug vedotin, acquired through the $43 billion acquisition of Seagen, is a Phase 3 antibody-drug conjugate (ADC) targeting integrin beta-6 and delivering monomethyl auristatin E. In the Phase 3 SigVie-002 trial for non-squamous non-small cell lung cancer, it did not demonstrate a statistically significant improvement in overall survival compared to docetaxel, a standard second-line treatment. As a result, Pfizer recognized a $3.8 billion impairment charge related to these assets. This will lead to a reassessment of the success rate of late-stage development assets and the recovery period for the Seagen acquisition price in the competitive lung cancer market, which already includes Keytruda (pembrolizumab), Opdivo (nivolumab), and several other late-stage ADCs.

Oxbryta Withdrawal Highlights Risks of Acquired Assets

Oxbryta (voxelotor), acquired through the acquisition of Global Blood Therapeutics, is an approved treatment that inhibits sickle hemoglobin polymerization and received accelerated approval from the FDA on November 25, 2019. Pfizer discontinued global sales and clinical trials on September 25, 2024, citing an imbalance in vascular occlusion crises and mortality events, and recognized an additional $525 million impairment charge in the second quarter of 2026. Given that hydroxyurea, Endari (L-glutamine), and Adakveo (crizanlizumab) with hematopoietic stem cell transplantation remain as treatment options, this highlights the financial costs of post-acquisition safety management in addition to the loss of patient access.

The Quality of Non-COVID Growth and Cost Savings is Key

Second-quarter revenue was approximately $15 billion, a 1% increase year-over-year, with the non-COVID portfolio growing by 5%. The company has raised the lower end of its 2026 revenue guidance to $60.5 billion, with a range of $60.5 billion to $62.5 billion. Eliquis (apixaban, a factor Xa inhibitor) generated $6.494 billion in 2025 revenue, while the Vynkeleis portfolio (tavapadis, a transthyretin stabilizer) generated $6.38 billion, and Ibrance (palbociclib, a CDK4/6 inhibitor) generated $4.12 billion, offsetting the decline in COVID-19 revenue. The additional cost savings include approximately $1.5 billion in manufacturing costs and efficiencies in commercial, research and development, and support organizations. Therefore, the focus of investment decisions is not just on the scale of cost savings, but on whether it translates into improved research and development productivity and operating margins.